NCT03277274View on ClinicalTrials.gov

A Study to Evaluate the Effect of Hepatic Impairment on the Single Dose Pharmacokinetics (PK) of Intravenous TAK-954

PHASE1CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

November 9, 2017

Primary Completion Date

September 1, 2018

Study Completion Date

September 10, 2018

Conditions
Hepatic ImpairmentHealthy Volunteers
Interventions
DRUG

TAK-954

TAK-954 intravenous infusion.

Trial Locations (2)

83101

Summit Center of Clinical Research, Bratislava

170 00

PRA CZ, s.r.o, Prague

Sponsors

Lead Sponsor

Takeda
All Listed Sponsors
lead

Takeda

INDUSTRY

NCT03277274 - A Study to Evaluate the Effect of Hepatic Impairment on the Single Dose Pharmacokinetics (PK) of Intravenous TAK-954 | Biotech Hunter | Biotech Hunter